Pfizer has the experience and resources to develop and manufacture biosimilar medicines

Biosimilar medicines are part of the future of biologic treatment, and Pfizer Biosimilars is committed to working at every level to make the full potential of biosimilar medicines a reality across the communities we serve.

For 30 years, Pfizer has dedicated significant resources to providing high-quality biologic medicines and selecting exceptional supply partners, with a development program supported by robust clinical and analytical data. Pfizer continues building on this through Pfizer Biosimilars, leveraging nearly 10 years of additional experience with biosimilars outside the United States.^1,2